Nation

Indian vaccine maker Serum Institute of India will manufacture a new Covid-19 vaccine for a crucial clinical trial being carried out by the researchers at Oxford University.

Indian firm makes Covid-19 vaccine for Oxford trials; DBT also funds three home-grown vaccines against the pandemic

New Delhi, April 24: Indian vaccine maker Serum Institute of India will manufacture a new Covid-19 vaccine for a crucial clinical trial being carried out by the researchers at Oxford University.

The vaccine is a weakened version of a common cold virus (adenovirus) from chimpanzees that has been genetically tweaked in such a way that it is impossible to grow in humans. To this virus, the scientists have further added genes to help the body identify a Covid-19 infection and put up a defence against the rampaging virus.

“SII will be manufacturing the vaccine in anticipation of clinical trials succeeding by September – October in the UK. The vaccine will not be made available to the public in two-three weeks as suggested in some media reports,” the company said in a statement.

The Oxford product (ChAdOx1 n-Cov-19) is one of the forerunners of the Covid-19 shots being developed around the world. More than 1,100 participants are to be recruited in study sites in Oxford, Southampton, London and Bristol to evaluate the vaccine that was found safe for use in humans.

The company said it decided to produce the vaccine at its own risk to have a jump start on the manufacturing so that enough doses become available, if the trials work.

With funding support from the Department of Biotechnology, the SII would also initiate a phase-3 clinical trial of recombinant BCG vaccine among high-risk Covid-19 patients.

The DBT approval came earlier this week following scientific observations that nations that offer BCG vaccine to the newborns have lower Covid-19 caseloads and deaths.

“It is an astute observation that in countries with universal infant BCG, there is less transmission and death than in countries without universal BCG. This question is being investigated in Germany and Australia. We shall wait and see their results,” commented T Jacob John, an eminent virologist and retired professor of clinical virology in Christian Medical College Vellore.

Under the National Biopharma Mission, the DBT has also funded Cadila Healthcare Ltd for a DNA vaccine candidate and Bharat Biotech for its inactivated rabies vector platform-based vaccine candidate.

The three vaccine projects are among the 16 programmes that DBT approved for funding to develop (or repurpose) vaccines, diagnostics and drugs to battle the Covid-19 pandemic.

8 Comments

8 Comments

Leave a Reply

Your email address will not be published.

4 × 2 =

News is information about current events. News is provided through many different media: word of mouth, printing, postal systems, broadcasting, electronic communication, and also on the testimony of observers and witnesses to events. It is also used as a platform to manufacture opinion for the population.

Contact Info

Address:
D 601  Riddhi Sidhi CHSL
Unnant Nagar Road 2
Kamaraj Nagar, Goreagaon West
Mumbai 400062 .

Email Id: [email protected]

West Bengal

Eastern Regional Office
Indsamachar Digital Media
Siddha Gibson 1,
Gibson Lane, 1st floor, R. No. 114,
Kolkata – 700069.
West Bengal.

Office Address

251 B-Wing,First Floor,
Orchard Corporate Park, Royal Palms,
Arey Road, Goreagon East,
Mumbai – 400065.

Download Our Mobile App

IndSamachar Android App IndSamachar IOS App
To Top
WhatsApp WhatsApp us